Qualify patients & measure efficacy of treatment using visuospatial & cognitive deficits
Collaborate with us Today
Tracking disease progression is critical for creating effective interventions
We see a new standard of care where patients, clinicians, and researchers can quickly and easily identify neurodegenerative disease in-office, enabling opportunities to intervene to save individuals, families, and communities.
We increase patient access to care and clinical decision making ability with our screening diagnostic. Our AI tracks neurodegeneration by identifying visuospatial & cognitive deficits from EEG patterns that indicate specific levels of amyloid and tau protein accumulation as well as cognitive impairment.
Learn more about our progress
Vistim Labs’ high-resolution biomarkers correlate with traditional PET/CSF & cognitive endpoints
Would you like to publish together as research partners?